Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (5733)	2/13/2004 3:56:46 PM
From: Janice Shell	Respond to of 12465

LOL!! I remember GUMM from years and years ago. There was something funny about it...

To: Jeffrey S. Mitchell who wrote (5733)	2/17/2004 2:23:41 PM
From: StockDung	Respond to of 12465

2/17/03 DJ Matrixx Has Contacted FDA About Zicam Cold Remedy By Carol S. Remond Of Dow Jones Newswires NEW YORK (Dow Jones)--Matrixx Initiatives Inc. (MTXX) says that it will cooperate with the Food and Drug Administration and answer any questions that the government agency may have about the safety of Zicam Cold Remedy. Matrixx Chief Executive Officer Carl Johnson told investors during a conference call Tuesday that the company has not "been informed by the FDA of an inquiry or an investigation." Johnson said reports linking Zicam Cold Remedy to anosmia, or loss of smell, are "misleading and completely unfounded." "However, reflecting our concern for this issue, we have taken the unusual step of communicating with the FDA, providing them with copies of our public statements on this matter. And we assured them that we will cooperate openly and fully should they have any questions what so ever regarding this matter," Johnson said. Dow Jones first reported on Jan. 30 in an "In The Money" column that the FDA is looking into complaints that Zicam Cold Remedy, a spray designed to deliver a zinc gel into the nose, may be causing some users to lose their sense of smell. Other news organizations have since reported similar stories. So far, five lawsuits have been filed against Matrixx by users of Zicam Cold Remedy who claim to have lost their sense of smell after using the product. An FDA spokeperson wasn't immdiately available to comment on Johnson's statements. Commenting on a statement by Matrixx on Feb.2 that it wasn't aware of an FDA inquiry, FDA's spokesman Brad Stone said "if the company wasn't aware that we are looking into this matter, it should be aware of it at this point...It's a matter of public record that we are looking into it." The company's stock is currently trading at $10.59, up 39 cents or 3.8%, on volume of 315,531 shares. -By Carol S. Remond; Dow Jones Newswir